NGD 97-1: Began Phase II testing

Neurogen Corp. (NRGN), Branford, Conn. Product: NGD 97-1 Business: Neurological Therapeutic category: Neurotransmission, Receptor agonist Target: GABA receptors Description: Small molecule selective i...